871507-79-8

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
2,8-Dibromoquinoline is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Antifungal Applications:
2,8-Dibromoquinoline is used as an antifungal agent, exhibiting potential activity against various fungal species, which could be beneficial in treating fungal infections and controlling fungal growth in agricultural settings.
Used in Organic Electronic Devices:
Due to its unique electronic and optical properties, 2,8-Dibromoquinoline is being investigated for potential applications in organic electronic devices, such as organic light-emitting diodes (OLEDs) and organic solar cells, where it could enhance device performance and efficiency.

Upstream product

• 615-36-1 2-bromoaniline 
• 71910-51-5 N-(2-bromophenyl)-3-phenylacrylamide 
• 67805-67-8 8-bromo-1H-quinoline-2-one 

Downstream Products

• 1262757-99-2 2,8-bis(2-methoxymethoxy-3,5-di-tert-butylphenyl)quinoline 
• 1418268-29-7 N-(2,6-diisopropylphenyl)-2-phenyl-8-quinolinamine 
• 1418268-30-0 N-(2,6-diisopropylphenyl)-2-(4-tert-butylphenyl)-8-quinolinamine 
• 1418268-31-1 N-(2,6-diisopropylphenyl)-2-(4-methylphenyl)-8-quinolinamine 
• 1418268-32-2 N-(2,6-diisopropylphenyl)-2-(4-fluorophenyl)-8-quinolinamine 
• 1418268-33-3 C₄₁H₄₀N₂Zr 
• 1418268-34-4 C₄₁H₄₀HfN₂ 
• 1259016-72-2 C₄₁H₃₄N₂Zr 
• 1259016-73-3 C₄₁H₃₄HfN₂ 
• 1259016-76-6 C₄₅H₄₂N₂Zr 
• 1259016-74-4 C₄₅H₄₂HfN₂ 
• 1431846-96-6 C₃₃H₃₉NO₄ 
• 1431846-98-8 8-bromo-2-[2-(methoxymethoxy)[1,1'-biphenyl]-3-yl]quinoline 
• 1345669-70-6 8-bromo-2-(4-methylphenyl)quinoline 

Relevant academic research and scientific papers

New tridentate cyclometalated platinum(II) and palladium(II) complexes of N,2-diphenyl-8-quinolinamine: Syntheses, crystal structures, and photophysical properties

A new tridentate cyclometalated platinum(II) complex derived from N,2-diphenyl-8-quinolinamine, which consists of two crystallographic independent molecules with two intermolecular N-H-Cl-Pt hydrogen bonds forming a dimer, exhibited a low-energy luminesce

Fe and Co Complexes of Rigidly Planar Phosphino-Quinoline-Pyridine Ligands for Catalytic Hydrosilylation and Dehydrogenative Silylation

Co and Fe dihalide complexes of a new rigidly planar PNN ligand platform are prepared and examined as precatalysts for hydrosilylation of alkenes. Lithiation of Thummel's 8-bromo-2-(pyrid-2′-yl)quinoline followed by treatment with (i-Pr)2PCl and (C6F5)2PCl afforded the phosphine-quinoline-pyridine ligands, abbreviated RPQpy for R = i-Pr and C6F5, respectively. These ligands form 1:1 adducts with the dichlorides and dibromides of iron and cobalt. Crystallographic characterization of FeBr2(iPrPQpy), FeBr2(ArFPQpy), CoCl2(iPrPQpy), CoBr2(iPrPQpy), and CoCl2(ArFPQpy) confirmed that the M-P-C-C-N-C-C-N portion of these complexes is planar within 0.078 ? unlike previous generations of PNN complexes where deviations from planarity were ～0.35 ?. Bond distances as well as magnetism indicate that the Fe complexes are high spin and the cobalt complexes are high spin or participate in spin equilibria. Also investigated were the NNN analogues of the RPQpy ligands, wherein the phosphine group was replaced by the mesityl ketimine. The complexes FeBr2(MesNQpy) and CoCl2(MesNQpy) were characterized crystallographically. Reduction of MX2(RPQpy) complexes with NaBHEt3 generates catalysts active for anti-Markovnikov silylation of simple and complex 1-alkenes with a variety of hydrosilanes. Catalysts derived from MesNQpy exhibited low activity. Fe-RPQpy derived catalysts favor hydrosilylation, whereas Co-RPQpy based catalysts favor dehydrogenative silylation. Catalysts derived from CoX2(iPrPQpy) convert hydrosilanes and ethylene to vinylsilanes. Related experiments were conducted on propylene to give propenylsilanes.

Iron Complexes of Square Planar Tetradentate Polypyridyl-Type Ligands as Catalysts for Water Oxidation

The tetradentate ligand, 2-(pyrid-2′-yl)-8-(1″,10″-phenanthrolin-2″-yl)-quinoline (ppq) embodies a quaterpyridine backbone but with the quinoline C8 providing an additional sp2 center separating the two bipyridine-like subunits. Thus, the four

Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor

Poly(ADP-ribose)polymerase-1 is an important target enzyme in drug design; inhibitors have a wide variety of therapeutic activities. A series of quinoline-8-carboxamides was designed to maintain the required pharmacophore conformation through an intramolecular hydrogen bond. 3-Substituted quinoline-8-carboxamides were synthesized by Pd-catalyzed couplings (Suzuki, Sonogashira, Stille) to 3-iodoquinoline-8-carboxamide, an efficient process that introduces diversity in the final step. 2-Substituted quinoline-8-carboxamides were prepared by selective Pd-catalyzed couplings at the 2-position of 2,8-dibromoquinoline, followed by lithium-bromine exchange of the intermediate 2-(alkyl/aryl)-8-bromoquinolines and reaction with trimethylsilyl isocyanate. The intramolecular hydrogen bond was confirmed by X-ray and by NMR. The SAR of the 3-substituted compounds for inhibition of human recombinant PARP-1 activity showed a requirement for a small narrow group. Substituents in the 2-position increased potency, with the most active 2-methylquinoline-8-carboxamide having IC50 = 500 nM (IC50 = 1.8 μM for 5-aminoisoquinolin-1- one (5-AIQ, a standard water-soluble inhibitor)).

IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.

IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula (I) in which A, B, R1, R1a, R2, R3, R4, R5, R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1